AC Immune SA (fra:IMR) Share Price

Company Profile

Business description
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Contact
EPFL Innovation Park
Building B
Lausanne1015
CHE
T: +41 213459121
E: [email protected]
https://www.acimmune.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
172

Recommended

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.

Joseph Taylor | 16 September 2025

Working to prevent repeated failures could also improve competitiveness.

Nathan Zaia | 15 September 2025

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Roy Van Keulen | 15 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,151.20	1.30	-0.01%
CAC 40	7,818.22	78.71	-1.00%
DAX 40	23,329.24	419.62	-1.77%
Dow JONES (US)	45,757.90	125.55	-0.27%
FTSE 100	9,195.66	81.37	-0.88%
HKSE	26,438.51	8.05	-0.03%
NASDAQ	22,333.96	14.79	-0.07%
Nikkei 225	44,902.27	134.15	0.30%
NZX 50 Index	13,234.89	26.58	0.20%
S&P 500	6,606.76	8.52	-0.13%
S&P/ASX 200	8,877.70	3.00	-0.03%
SSE Composite Index	3,861.86	1.36	0.04%